

An exclusive thought leadership event, bridging the gaps
in Australia's vaccine ecosystem to maximise health impact and
unlock the nation's economic potential in global disease prevention

AUSTRALIA'S Vaccine Value Chain

CONFERENCE
Sydney 2024

Collaborate • Innovate • Achieve

Sponsorship Prospectus



We would like to acknowledge the traditional owner of the lands and pay our respects to Elders both past and present.

Contents

Foreword	1
About the Conference	3
Why Vaccines?	6
Vaccine Conference	9
Sponsorship Opportunities	12
Application Form	15



Sponsors

Diamond sponsor



Platinum sponsor



Gold sponsors

Supported by the



Silver sponsors



Bronze sponsors

This event supported by



Contributors



Foreword

From the Inaugural Program Committee

There are many aspects involved in the value chain of vaccines from discovery through to implementation. However, our understanding of all the challenges, barriers, and levers to streamline this value chain across all key stakeholders is fragmented and sometimes siloed in Australia's federated system.

This was quite evident in our response to the COVID-19 pandemic where novel vaccines were developed globally in record time. Australia's public health ecosystem pulled together, but the gaps became clear. Since then, there have been many lessons learnt and significant investment by jurisdictional and Federal Governments, the private sector and philanthropy into different parts of the ecosystem.

While Australia has strengths in many areas, such as discovery research, the knowledge and experience to translate discoveries effectively, to truly impact the health of the community, requires data availability, resources and know-how all along the value chain. Access to funding and skilled workforce remains fragmented across our ecosystem, and this affects our ability to capitalise on our research strengths in infectious diseases and immunology.

With less than 2% of the Australian health budget being spent on prevention, we place much greater emphasis (and resourcing) on treating than preventing disease. Lengthy review processes for vaccines, triggered by industry applications, and followed by tendering for the National Immunisation Program, delay access and may create disincentives to launch new vaccines in Australia. We need to develop preventive health strategy that accelerates access to routine vaccines as well as prepare for disease outbreaks.

Australia has a world-leading track record in childhood immunisation programs. Among adults, vaccine fatigue, vaccine hesitancy, equity of access and uptake are all current issues of concern for the immunisation community, with consumer engagement and knowledge of vaccines forever changed. We also have an important leadership role to play in the region to support our more vulnerable neighbours.

Recent breakthroughs like mRNA technology have revolutionised the speed of vaccine development and will allow new diseases to be targeted and may allow for streamlined regulatory and development pathways.

There are expansive opportunities for Australia as a southern hemisphere centre of real world safety and effectiveness studies of vaccines. This would simultaneously strengthen our understanding of the impacts of vaccines on public health outcomes in Australian while contributing to the global evidence base.

We need to ensure that all aspects of policy and regulation, including health technology assessment, keep pace. Some targets may not be commercially attractive and may require public private partnerships to support commercialisation and access for the most vulnerable populations.

With large investments being funnelled into the ecosystem to build manufacturing capabilities, fund discovery and translational research, and growth of the healthcare sector, it is paramount to unite all pivotal stakeholders within the vaccine value chain. This will boost our ability to collaborate and build innovation capacity with the goal of maximising health and economic benefits in Australia and our region.

Set on 21st – 22nd of May in Sydney, Australia’s Vaccine Value Chain Conference promises a deep dive into the future of vaccine innovation, featuring insights from renowned international and local experts. This unparalleled gathering will delve into the nuances of vaccine development, manufacturing, clinical trials, commercialisation, and more, offering a holistic view of the entire value chain.

For the first time, key decision-makers and thought leaders from government, industry, academia, NGOs, and representatives from the immunisation community will converge, highlighting the transformative potential of collaborative innovation.

Seize this unique opportunity to align your brand with the future of vaccine advancements. Your involvement can make a significant difference; let’s redefine the vaccine landscape collaboratively.




Jenny Herz

Co-founder and
Strategic Advisor,
Biointellect



Branwen Morgan

Lead,
Minimising AMR Mission
Research Director,
Health & Biosecurity, CSIRO




Kieran Schneemann

Independent
Consultant



Jodie McVernon

Professor and Director of
Doherty Epidemiology
Head, VIDRL Epidemiology
Unit, Department of
Infectious Diseases



John Skerritt

Enterprise Professor for
Health Research Impact,
University of Melbourne



Ian Henderson

Executive Director,
Institute for Molecular
Bioscience, UQ



David Grolman

Medical mRNA
and Antiviral Lead,
Pfizer Australia



Alma Fulurija

Head of Strep A Vaccines
Telethon Kids



Leanne Hobbs

Independent consultant

About the Conference

There is an urgent need to bring together all the key stakeholders in the Australian vaccine value chain to better understand some of the key challenges, address the gaps, and enhance collaboration to drive innovation and productivity. This will also help to avoid duplication, increase our global competitiveness, and ultimately have a positive impact on the health and wellbeing of Australians.

Attendees

- Key opinion leaders and clinicians
- State and Federal Governments from all Australian States
- Representatives from the immunisation community including NGOs
- Research Institutes and Universities
- Vaccine researchers
- Industry including multi nationals and SME's and industry bodies
- Pharmacists and General Practitioners
- Patient advocacy groups


Outcomes

The conference focuses on the end-to-end vaccine value chain and highlighting the importance of bringing all stakeholders in the ecosystem together to address gaps, learn from overseas experiences or local best practices, and propose actionable solutions.

- Knowledge sharing and network creation to generate deep understanding between attendees to learn from each other about the end-to-end vaccine value chain.
- Identify strengths and weaknesses in the value chain, including data, infrastructure, talent, funding, policy and regulation with tangible recommendations for change.
- Understand what we mean by sovereign capability and how Australia can be relevant and competitive in the global context while also supporting the region.
- Identify the opportunities to collaborate for change and show the value of partnership to drive innovation
- Identify key areas to accelerate access to vaccines and strengthen decision making, including HTA. methods, processes and procurement models.
- Explore how policy and regulation can enable an end-to-end value chain that maximises health impact and economic development while ensuring that Australians have access to cutting edge innovations.

If we achieve this, the benefits could include increasing our competitiveness, accelerating the commercialisation of new vaccines, and improving public health outcomes. This is consistent with Australia's draft National Science and Research Priorities:

- Building a stronger and more resilient nation.
- Strengthening existing industries and driving innovation.
- Leading on preventive health.
- Supporting health communities.
- Ensuring equitable access to health care.



Topics

- Identifying gaps in the ecosystem and the need to build capability and capacity in Australia.
- Talent workforce across the value chain and skills gap shortages.
- Encourage education and a deeper understanding between different parts of the vaccine ecosystem.
- How to harness and translate our strengths in research and leverage new technologies to position Australia in the global supply chain.
- Challenges at the frontline with community access including vaccine hesitancy into tangible outcomes/ solutions and impact.
- Policy and regulation of vaccines to support Australia and our region including the HTA.
- Stimulating innovation through public-private partnerships to target infectious diseases with limited commercial return.
- Supporting the region and disadvantaged communities to equitable access and uptake of vaccines.
- Sustainability of the vaccine business case for pandemic preparedness and emerging infectious diseases.

Specifications

The aim is to run this event annually, rotating the location to one of the Australian States. This inaugural event will be hosted in NSW on the 21st and 22nd of May 2024 with the following specifications:

- ~200+ key stakeholders and decision makers around Australia.
- Invitation-only event including various networking events as potential sponsorship opportunities.
- The program committee, which includes experts from all fields of vaccinology in the public and private sector, is committed to fostering comprehensive diversity, equity, and inclusion standards throughout the appointment, ensuring a diverse representation that reflects and respects the wider community.
- Robust governance model to ensure independence, balanced input from all stakeholders and proper management of potential conflicts of interest.
- At the end of the first conference, the key summary and takeaways from the conference that could effect change will be provided to all participants as a white paper.
- A vaccine community with greater appreciation for each other's perspectives on the future vision of the vaccine ecosystem in Australia, opening the door to greater collaboration and innovation.



Why Vaccines?

The Gap

Australia has many strengths, including world-leading infectious disease physicians and scientists, strong vaccine R&D ecosystem, and a favourable and dynamic clinical trials environment. However, Australia has struggled to effectively translate these advantages to commercialisation of new vaccines as the innovation chain remains fragmented and a number of products fail to have clear commercialisation strategies.

The Technical Opportunity

Successes with rapid and effective vaccine development during the COVID-19 pandemic; recent major commercial investments in mRNA and viral vector manufacturing in Australia; increased focus on development and access to vaccines for adults; recent promising results with decades-long challenges for vaccination against major diseases including HIV, malaria and cancers.

A Range of Urgent Policy Issues to Address

Government and industry decisions on Australian sovereign manufacturing capacity; establishment of the new Australian Centre for Disease Control; the new DFAT Department of Foreign Affairs and Trade (DFAT) Partnerships for a Health Region Initiative, which include a focus on vaccine development and deployment in Asia-Pacific; and the Health Technology Assessment (HTA) review is currently underway.

Adult Vaccination Uptake Remains Low


There is work to do to improve equity for rural, remote, and regional populations, such as increasing visibility of population data. This needs attention in the post-COVID context of increased consumer knowledge, vaccine hesitancy and covid fatigue.






Addressing the End-to-End Vaccine Value Chain

The vaccine value chain encompasses the linear development process from basic research and development all the way through to market access. On average this process takes 8 to 14 years, accompanied by a cost ranging from \$550 to \$1000 million with a success rate of approximately 7%.



Interaction Between Key Stakeholders in the Vaccine Value Chain is Crucial

The success of the value chain depends on the ability of stakeholders to work together effectively and to balance the interests of the community, investors, and regulatory authorities. Each stakeholder has their own interests and incentives that influences the decision-making processes, collaboration, and overall efficiency of the ecosystem.



Vaccine Conference



Date

Tuesday 21st and Wednesday 22nd of May 2024

Location

Doltone House Hyde Park, Sydney (NSW)

Target attendees

200+

Conference format

Plenary sessions, panel sessions, networking events and a sponsored satellite session

Focus

Eight themes:

- Vaccine value chain
- Governance, skills and talent
- Infrastructure and clinical trials
- Public health policy and regulations
- Market access and HTA
- Vaccine equity and uptake
- Supply, demand, and sustainability
- Funding and investment

Output

- A white paper with a series of recommendations
- Commitment for an annual event
- Creation of a national vaccine network

Preliminary Conference Program*

DAY 1 – TUESDAY 21ST MAY 2024

*Proposed Conference Program is subject to input from sponsors.

8:30am – 8:50am

Opening of the Conference

- Welcome to country
- Opening remarks

8:50am – 10:15am

Plenary 1: The Vaccine Value Chain – What Do We Want for Australia?

This session will introduce the concept of the vaccine value chain, present insights from successful international models, the Australian experience and discuss how we can measure and improve research impact and commercialisation.

10:15am – 10:45am

Morning Team and Networking

11:45am – 12:00pm

Plenary 2: Preclinical Vaccine Development Capabilities in Australia: Governance, Skills and Talent

This session explores pre-clinical vaccine development in Australia including some of our unique strengths, highlights the challenges in funding, skills and governance and includes some local and international models as exemplars for change.

12:00pm – 1:00pm

Lunch and Networking Event

1:00pm – 2:15pm

Plenary 3: Clinical Trials and Infrastructure

This session will provide different perspectives on clinical trial capability, from industry, academia, NGOs, and from early stage trials through to large phase 3 international trials. The panel will discuss how Australia can grow its global share of vaccine trials and attract industry investment as well as improve access for underserved populations.

2:15pm – 3:30pm

Plenary 4: Manufacturing: Supply, Demand and Sustainability

This session will outline the goals of the NRF and the strategic importance of Sovereign Manufacturing, before moving on to explore different perspectives from industry with respect to supply chain and manufacturing. It then critically examines the pressing challenges and central issues surrounding the supply and demand dynamics of vaccines, emphasising the balance of local and global strategies for a robust and resilient vaccine ecosystem for the future..

3:30pm – 4:30pm

Afternoon Tea and Networking

4:30pm – 5:30pm

Plenary 5: Enabling Policy and Regulation for Vaccines

This session offers an update on the Australian Centre for Disease Control, delves into the enabling regulations for cutting-edge platform technologies, particularly highlighting the potential of mRNA for human and veterinary vaccines. It also provides insights into the latest developments in the National Immunisation Strategy and underscores the relationship between evidence-based evaluation, public and animal health policies and the regulation of vaccines.

6:00pm – 10:00pm

Dinner and Evening Networking

DAY 2 – WEDNESDAY 22ND MAY 2024

8:00am – 8:30am **Networking Breakfast**

8:30am – 9:45am **Special Plenary: How Can Australia Contribute to Advance CEPI's 100 Day Mission and the Regional Vaccine Manufacturing Initiative?**

9:45am – 11:00am **Plenary 6: Equity of Access and Uptake**

This session delves deep into Australia's pivotal role and challenges in vaccine distribution and advocacy, drawing lessons from the COVID-19 pandemic and insights from CEPI and DFAT's regional health priorities. The session also sheds light on the prevalent issue of vaccine hesitancy, with lessons learned from Australia's HPV campaign. Furthermore, the session examines adult vaccine uptake, particularly focusing on the unique challenges of delivering vaccines underserved and hard to reach populations and the need for evidence informed approaches to privileging access to achieve equitable health outcomes. The session underscores the significance of effective communication strategies for emphasizing the importance and benefits of vaccines and vaccination.

11:00am – 11:30am **Morning Tea and Networking**

11:30am – 12:45pm **Plenary 7: Market Access and Health Technology Assessment**

This session presents the latest findings from the Health Technology Assessment (HTA) review and discusses the specific considerations of vaccines within the HTA framework. It delves into the challenges of access delays, related to evidence, systems and processes, offering a comparative perspective with overseas practices and emphasizing the community's viewpoint on the value of vaccines.

12:45pm – 1:45pm **Lunch and Networking**

1:45pm – 3:00pm **Plenary 8: Funding and Investment**

This session opens with strategies for financing vaccine commercialisation and spurring new innovations. It then ventures into the challenge of stimulating vaccine development for diseases that offer limited financial returns. The session underscores the role and potential of Public-Private Partnerships within Australia and concludes with a critical examination of where funding and investment should be channelled to ensure optimal outcomes for both Australia and the broader region.

3:00pm – 3:45pm **Plenary 9: Bringing it All Together/ The Vaccine Value Chain**

The final interactive session will round off the conference by bringing all the discussions together to review the key areas within the Australian vaccine value chain. This session is envisaged as a round-table to give attendees the opportunity to reflect on various parts of the end-to-end process.

4:15pm – 5:30pm **Satellite Session: Advancing Innovation in Australian Veterinary Vaccines**

The advent and use of new technologies and platforms has significantly expedited vaccine development with the ability to rapidly target new diseases. This creates opportunities to streamline product development and regulatory pathways. The objective of this session is to identify ways for Australia to keep pace with these advances and to deliberate current innovations and future trends for veterinary vaccines. **Convened by CSIRO.**

Sponsorship Opportunities



Why Partner with us?

The sponsorship packages have been designed to provide your organisation with maximum exposure to conference delegates.

As an invite-only event, the conference will provide an ideal forum for knowledge exchange, facilitate interactions and networking with the key players from government, regulatory, community and research institutes.

Benefits to Sponsorship

- Network and build new relationships with key Australia-based stakeholders.
- Be openly acknowledged for your support.
- Promote your organisation, services, and products.
- Increase and strengthen brand awareness.



PACKAGE

	Contributor	Bronze	Silver
	REGISTRATION		
Registration	1 delegate pass included	2 delegate pass included	4 delegate passes included
Discount to additional sponsorship opportunities			5%
Reception and dinner	1 delegate pass included	2 delegate pass included	4 delegate passes included
Speaker opportunity			
	MARKETING & PROMOTION		
Your organisation logo to be included on marketing collateral	Basic	Basic	All
Organisational profile in conference brochure		1/5 page 25 words	1/4 page 50 words
Verbal acknowledgement as a sponsor in the opening session of the conference			
Display a pull up banner in the foyer		✓	✓
Exclusive naming rights to a part of the program, including: <ol style="list-style-type: none"> 1. Plenary Session in collaboration with an international speaker selected by the program committee 2. Plenary Session in collaboration with an international speaker of choice 			
PRICE	AUD \$2,000 – \$5,000	AUD 10,000	AUD 30,000

All prices are in AUD and exclude GST.

PACKAGE

	Gold	Platinum	Diamond
		REGISTRATION	
Registration	6 passes included	12 passes included	
Discount to additional sponsorship opportunities	10%	15%	
Reception and dinner	6 passes included	12 passes included	
Speaker opportunity		1 speaker opportunity no parallel sessions OR 1 session chair	
	MARKETING & PROMOTION		
Your organisation logo to be included on all marketing collateral	All	All	
Organisational profile in conference brochure	1/5 page 100 words	1 page 500 words	
Verbal acknowledgement as a sponsor in the opening session of the conference	✓	✓	
Display a pull up banner in the foyer	✓	✓	
Exclusive rights to a satellite session			
Exclusive naming rights to a part of the program, including:			
<ol style="list-style-type: none"> Plenary Session in collaboration with an international speaker selected by the program committee Plenary Session in collaboration with an international speaker of choice 	Option 1	Option 2	
PRICE	AUD 50,000	AUD 100,000	

All prices are in AUD and exclude GST.

Additional Sponsorship Opportunities

Pre-Conference/Sponsored Sessions and Presentation Opportunities

▶ **Private Meeting Room – SOLD OUT**

Gain access to a dedicated room to host delegates and guests and dive deeper into the various discussions surrounding the event. Meeting rooms are available for half day, single day and full conference durations.

Promotion and Brand Awareness Opportunities

The following opportunities are limited and will be allocated to sponsors on a first in first served basis.

▶ **Wi-Fi Sponsorship**

Provide the connection for the Meeting and every delegate will be made aware that your organization is keeping them online.

▶ **Mobile Charging Stations**

Brand the mobile device, laptop and tablet charging station and help meeting attendees stay powered up and connected.

▶ **Welcome Reception**

Sponsors have the opportunity to brand the opening reception to the conference or set up their own station to interact directly with delegates.

▶ **Networking Opportunities**

Sponsors have the opportunity to brand the coffee/lunch stations or set up their own station to interact directly with delegates.

▶ **Dinner Sponsorship**

Sponsors have the opportunity to sponsor the dinner on the first evening of the conference.

▶ **Hydration Stations**

Keep delegates hydrated and have your brand recognised at a beverage station(s) throughout the conference venue or take it to the next level and man the station yourself to interact directly with attendees.

Other Sponsorship Opportunities

We are always looking to expand our sponsorship offerings and are committed to working with our partners to find the right fit for their organisation. If you have additional ideas on how your organisation can support the event, please contact us to discuss how we can help.

Sponsorships are subject to the terms and conditions supplied with this document.

Application Form

Organisation Name	<input type="text"/>		
ABN	<input type="text"/>		
Contact Person	<input type="text"/>		
Position	<input type="text"/>		
Email	<input type="text"/>		
Telephone	<input type="text"/>		
Mobile Number	<input type="text"/>		
Address	<input type="text"/>		
State	<input type="text"/>	Postcode	<input type="text"/>
Country	<input type="text"/>		
Website	<input type="text"/>		

Sponsorship

Please indicate below the requested Sponsorship Package:

Contributor 2-5K

Bronze 10K

Silver 30K

Gold 50K

Platinum

Diamond – SOLD OUT

Additional Sponsorship

- Wi-Fi Sponsorship
- Mobile Charging Stations
- Welcome Reception
- Networking Opportunities
- Pre/Post Conference Webinar
- Dinner Sponsorship
- Hydration Stations
- Private Meeting Room

Total Sponsorship Fees:

Payment schedule for Contributors: invoice due on accepting the Conference Terms and Conditions.

Payment schedule for Bronze packages and above: 50% will be due on execution of the Conference Terms and Conditions. Second payment of 50% will be due one month before the conference date.

I confirm that I have read and agree with the Terms & Conditions provided with this document.

Date

Signature


Once completed, please send the form to events@biointelect.com



Biointelect Pty Ltd ABN 17 154 647 051

Level 4, 143 Macquarie Street, Sydney NSW Australia 2000

Level 17, 31 Queen Street, Melbourne VIC Australia 3000

T 1300 800 984 E events@biointelect.com 

www.biointelect.com

The CSIRO logo and acronym are trade marks of CSIRO and used under licence.